Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de guselcumabe em participantes pediátricos com doença de Crohn moderada a gravemente ativa (MACARONI-23)

2 de novembro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo de plataforma de fase 3, multicêntrico, randomizado, da inibição de p19 da via de IL-23 para estabelecer a eficácia na doença de Crohn pediátrica

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

Visão geral do estudo

Status

Recrutamento

Condições

Tipo de estudo

Intervencional

Inscrição (Estimado)

120

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Nedlands, Austrália, 6009
        • Recrutamento
        • Perth Children's Hospital
      • South Brisbane, Austrália, 4101
        • Recrutamento
        • Mater Hospital Brisbane
      • Westmead, Austrália, 2145
        • Recrutamento
        • The Children's Hospital at Westmead
      • Campinas, Brasil, 13060-904
        • Recrutamento
        • Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
      • Curitiba, Brasil, 80250-060
        • Recrutamento
        • Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
      • Goiânia, Brasil, 74605-020
        • Recrutamento
        • Universidade Federal de Goias - Hospital das Clinicas da UFG
      • Porto Alegre, Brasil, 90035-074
        • Recrutamento
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasil, 90035-007
        • Recrutamento
        • Hospital De Clinicas De Porto Alegre
      • Vitória, Brasil, 29040-091
        • Recrutamento
        • Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
      • Votuporanga, Brasil, 100000
        • Recrutamento
        • INTEGRAL Pesquisa e Ensino
      • Brussels, Bélgica, 1090
        • Recrutamento
        • Universitair Ziekenhuis Brussel
      • Brussels, Bélgica, 1200
        • Recrutamento
        • Cliniques Universitaires Saint Luc
      • Ghent, Bélgica, 9000
        • Recrutamento
        • Universitair Ziekenhuis Gent
      • Leuven, Bélgica, 3000
        • Recrutamento
        • UZ Leuven
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3K 6R8
        • Recrutamento
        • Iwk Health Centre
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • Recrutamento
        • London Health Sciences Centre Victoria Hospital
      • Toronto, Ontario, Canadá, M5G 1X8
        • Recrutamento
        • Hospital For Sick Children
      • Busan, Coréia do Sul, 48108
        • Recrutamento
        • Inje University Haeundae Paik Hospital
      • Daegu, Coréia do Sul, 41404
        • Recrutamento
        • Kyungpook National University Chilgok Hospital
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 120-752
        • Recrutamento
        • Severance Hospital Yonsei University Health System
      • Córdoba, Espanha, 14004
        • Recrutamento
        • Hosp Reina Sofia
      • Sabadell, Espanha, 8208
        • Recrutamento
        • Corporacio Sanitari Parc Tauli
      • Valencia, Espanha, 46026
        • Recrutamento
        • Hosp. Univ. I Politecni La Fe
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Recrutamento
        • Cedars Sinai Medical Center
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06106
        • Recrutamento
        • Connecticut Children's Medical Center
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University
      • Atlanta, Georgia, Estados Unidos, 30342
        • Recrutamento
        • Children's Center for Digestive Health Care
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202-5225
        • Recrutamento
        • Riley Hospital for Children
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Recrutamento
        • Boston Childrens Hospital
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Recrutamento
        • Goryeb Children's Hospital
    • New York
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • Columbia University Medical Center
      • New York, New York, Estados Unidos, 10021-5663
        • Recrutamento
        • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    • Ohio
      • Dayton, Ohio, Estados Unidos, 45404
        • Recrutamento
        • The Children's Medical Center of Dayton
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Recrutamento
        • Cook Childrens Medical Center
    • Vermont
      • Colchester, Vermont, Estados Unidos, 05446
        • Recrutamento
        • University of Vermont Medical Center
      • Amiens, França, 80054
        • Recrutamento
        • CHU Amiens-Hopital Nord
      • Lille, França, 59037
        • Recrutamento
        • Hôpital Jeanne de FLANDRE, CHRU LILLE
      • Paris, França, 75019
        • Recrutamento
        • Hôpital Robert Debré
      • Paris, França, 75015
        • Recrutamento
        • Hôpital Necker - Enfants Malades
      • Rotterdam, Holanda, 3015 GD
        • Recrutamento
        • Erasmus Medisch Centrum
      • Beersheba, Israel, 84101
        • Recrutamento
        • Soroka University Medical Center
      • Be’er Ya‘aqov, Israel, 70300
        • Recrutamento
        • Shamir Medical Center Assaf Harofeh
      • Jerusalem, Israel, 9103102
        • Recrutamento
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9124001
        • Recrutamento
        • Hadassah Medical Center
      • Petah Tikva, Israel, 4920235
        • Recrutamento
        • Schneider Children's Medical Center
      • Rehovot, Israel, 761001
        • Recrutamento
        • Kaplan Medical Center
      • Alessandria, Itália, 15121
        • Recrutamento
        • A.O. Santi Antonio e Biagio e Cesare Arrigo
      • Bergamo, Itália, 24127
        • Recrutamento
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Bologna, Itália, 40124
        • Recrutamento
        • Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
      • Florence, Itália, 50139
        • Recrutamento
        • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
      • Milan, Itália, 20154
        • Recrutamento
        • Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
      • Roma, Itália, 161
        • Recrutamento
        • AOU Policlinico Umberto I
      • Hirosaki, Japão, 036-8563
        • Recrutamento
        • Hirosaki University Hospital
      • Kagoshima, Japão, 890-8544
        • Recrutamento
        • Kagoshima University Hospital
      • Kashiwa-shi, Japão, 277-0871
        • Recrutamento
        • Tsujinaka Hospital Kashiwanoha
      • Kobe, Japão, 650 0017
        • Recrutamento
        • Kobe University Hospital
      • Saga, Japão, 849-8501
        • Recrutamento
        • Saga University Hospital
      • Sendai, Japão, 989-3126
        • Recrutamento
        • Miyagi Childrens Hospital
      • Setagaya Ku, Japão, 157 8535
        • Recrutamento
        • National Center for Child Health and Development
      • Tokyo, Japão, 113-8431
        • Recrutamento
        • Juntendo University Hospital
      • Tsu, Japão, 514 8507
        • Recrutamento
        • Mie University Hospital
      • Ube, Japão, 755-8505
        • Recrutamento
        • Yamaguchi University Hospital
      • Yokohama, Japão, 232-0024
        • Recrutamento
        • Yokohama City University Medical Center
      • Yokohama, Japão, 230-8765
        • Recrutamento
        • Saiseikai Yokohamashi Tobu Hospital
      • Nordbyhagen, Noruega, 1474
        • Recrutamento
        • Akershus Universitetssykehus HF
      • Oslo, Noruega, 424
        • Recrutamento
        • Oslo University Hospital
      • Tromsø, Noruega, 9038
        • Recrutamento
        • Universitetssykehuset Nord-Norge HF
      • Trondheim, Noruega, 7030
        • Recrutamento
        • St. Olavs Hospital
      • Rzeszów, Polônia, 35-302
        • Recrutamento
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polônia, 04 501
        • Recrutamento
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polônia, 04 730
        • Recrutamento
        • Instytut Pomnik Centrum Zdrowia
      • Braga, Portugal, 4710-243
        • Recrutamento
        • Hospital de Braga
      • Lisbon, Portugal, 1649-035
        • Recrutamento
        • Centro Hospitalar de Lisboa Norte Hospital Santa Maria
      • Porto, Portugal, 4200-319
        • Recrutamento
        • Centro Hospitalar de Sao Joao E.P.E.
      • Glasgow, Reino Unido, G51 4TF
        • Recrutamento
        • Royal Hospital for Sick Children
      • London, Reino Unido, WC1N 3JH
        • Recrutamento
        • Great Ormond Street Hospital
      • Manchester, Reino Unido, M13 9WL
        • Recrutamento
        • Royal Manchester Children's Hospital
      • Manchester, Reino Unido, M13 9WL
        • Recrutamento
        • Nowgen Centre, Research and Innovation
      • Oxford, Reino Unido, OX3 9DU
        • Recrutamento
        • John Radcliffe Hospital
      • Sheffield, Reino Unido, S10 2TH
        • Recrutamento
        • Sheffield Children's Hospital
      • Vienna, Áustria, 1090
        • Recrutamento
        • AKH - Medizinische Universitat Wien

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

2 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)

Exclusion Criteria:

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Open-label induction phase: Guselkumab Intravenously (IV)

Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Outros nomes:
  • CTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Outros nomes:
  • CTO1959
  • TREMFYA
Experimental: Open-label induction phase: Guselkumab Subcutaneously (SC)

Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase.

Guselkumab will be administered subcutaneously.

Outros nomes:
  • CTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Outros nomes:
  • CTO1959
  • TREMFYA
Experimental: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Outros nomes:
  • CTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Outros nomes:
  • CTO1959
  • TREMFYA
Experimental: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2

At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Outros nomes:
  • CTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Outros nomes:
  • CTO1959
  • TREMFYA
Experimental: Open-label maintenance phase: Guselkumab SC

Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.

Guselkumab will be administered subcutaneously.

Outros nomes:
  • CTO1959
  • TREMFYA

Guselkumab will be administered intravenously.

Outros nomes:
  • CTO1959
  • TREMFYA

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants with Clinical Remission at Week 52
Prazo: Week 52

Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Prazo: Week 52

Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline.

Week 52

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants with Clinical Response at Week 12
Prazo: Week 12

Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 12
Percentage of Participants with Clinical Response at Week 52
Prazo: Week 52

Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30.

Week 52
Percentage of Participants with Clinical Remission at Week 12
Prazo: Week 12

Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 12
Percentage of Participants with Endoscopic Remission at Week 52
Prazo: Week 52

Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1.

Week 52
Percentage of Participants with Corticosteroid-free Remission at Week 52
Prazo: Week 52

Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52.

Week 52
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Prazo: Weeks 12, 24, and 52

Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52.

Weeks 12, 24, and 52
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Prazo: Week 12 and/or Week 52

Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline.

Week 12 and/or Week 52
Serum Concentration of Guselkumab During Induction Phase
Prazo: From Week 0 to Week 12

Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method.

From Week 0 to Week 12
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Prazo: At Weeks 16, 24, 36, 48 and 52

Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration.

At Weeks 16, 24, 36, 48 and 52
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in height at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Prazo: Baseline, Weeks 12, 24, and 52

Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed.

Baseline, Weeks 12, 24, and 52
Percentage of Participants with Clinical Remission
Prazo: Week 52

Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10.

Week 52
Percentage of Participants Who Achieve Endoscopic Response
Prazo: Week 52

Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline.

Week 52
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Up to Week 64

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

Up to Week 64

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de março de 2024

Conclusão Primária (Estimado)

27 de outubro de 2027

Conclusão do estudo (Estimado)

14 de agosto de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

20 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de junho de 2023

Primeira postagem (Real)

28 de junho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CR109212
  • 2021-006282-37 (Número EudraCT)
  • CNTO1959PBCRD3007 (Outro identificador: Janssen Research & Development, LLC)
  • 2023-504735-41-00 (Identificador de registro: EUCT number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever